SGSH

Across TCGA pan-cancer cohorts, SGSH mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SGSH data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SGSH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SGSH expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SGSH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.960	0.692	.004	17	view →
HNSC	OS	Median	All	0.344	1.000	.009	16	view →
LUAD	OS	Tertile	II,III,IV	0.771	0.402	.007	11	view →
UCEC	OS	Median	II,III,IV	0.628	1.000	.013	8	view →
CCRCC	OS	Median	All	1.000	0.920	.043	2	view →
LSCC	OS	Median	III,IV	0.944	0.764	.045	1	view →
GBM	DFS	Median	All	0.662	0.768	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SGSH–PDAC (OS)

Open the PDAC breakdown →